down arrow

Enwei Pharmaceutical Co., Ltd.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: CNE100005LC7
CNY
28.76
0.71 (2.53%)

Dec 05

SHE

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Comparison
Company
Score
Quality
Valuation
Financial
Technical
Enwei Pharmaceutical Co., Ltd.
Why is Enwei Pharmaceutical Co., Ltd. ?
1
Poor long term growth as Net Sales has grown by an annual rate of 8.51% and Operating profit at -13.04% over the last 5 years
2
Negative results in Mar 25
  • INTEREST(9M) At CNY 2.69 MM has Grown at 1,760.71%
  • OPERATING PROFIT(Q) Lowest at CNY 16.11 MM
  • OPERATING PROFIT MARGIN(Q) Lowest at 8.28 %
3
With ROE of 5.35%, it has a attractive valuation with a 1.00 Price to Book Value
  • Over the past year, while the stock has generated a return of 14.58%, its profits have risen by 43.8% ; the PEG ratio of the company is 0.4
stock-recommendationReal-Time Research Report
Verdict Report
How much should you hold?
  1. Overall Portfolio exposure to Enwei Pharmaceutical Co., Ltd. should be less than 10%
  2. Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is Enwei Pharmaceutical Co., Ltd. for you?

High Risk, Medium Return

Absolute
Risk Adjusted
Volatility
Enwei Pharmaceutical Co., Ltd.
-100.0%
0.28
42.60%
China Shanghai Composite
15.19%
1.01
15.10%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors
Factor
Value
Sales Growth (5y)
8.51%
EBIT Growth (5y)
-13.04%
EBIT to Interest (avg)
53.36
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.30
Sales to Capital Employed (avg)
0.65
Tax Ratio
16.24%
Dividend Payout Ratio
47.00%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
9.58%
ROE (avg)
5.60%
stock-recommendationValuation
Valuation Scorecard stock-summary
stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary
Factor
Value
P/E Ratio
19
Industry P/E
Price to Book Value
1.00
EV to EBIT
11.37
EV to EBITDA
6.39
EV to Capital Employed
1.00
EV to Sales
0.86
PEG Ratio
0.43
Dividend Yield
NA
ROCE (Latest)
8.78%
ROE (Latest)
5.35%
stock-recommendationTechnicals
Technical key factors
Indicator
Weekly
Monthly
MACD
Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Bearish
Dow Theory
No Trend
No Trend
OBV
No Trend
No Trend
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
Analyse All Technical Factors stock-recommendation
stock-recommendationFinancial Trend
Financial Trend Scorecard stock-summary
stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

10What is working for the Company
OPERATING CASH FLOW(Y)

Highest at CNY 101.73 MM

RAW MATERIAL COST(Y)

Fallen by -4.53% (YoY

PRE-TAX PROFIT(Q)

At CNY 17.99 MM has Grown at 71.43%

NET PROFIT(Q)

At CNY 16.31 MM has Grown at 93.56%

EPS(Q)

Highest at CNY 0.16

-10What is not working for the Company
INTEREST(9M)

At CNY 2.69 MM has Grown at 1,760.71%

OPERATING PROFIT(Q)

Lowest at CNY 16.11 MM

OPERATING PROFIT MARGIN(Q)

Lowest at 8.28 %

Here's what is working for Enwei Pharmaceutical Co., Ltd.
Operating Cash Flow
Highest at CNY 101.73 MM and Grown
In each year in the last three years
MOJO Watch
The company has generated higher cash revenues from business operations

Operating Cash Flows (CNY MM)

Pre-Tax Profit
At CNY 17.99 MM has Grown at 71.43%
Year on Year (YoY)
MOJO Watch
Near term Pre-Tax Profit trend is positive

Pre-Tax Profit (CNY MM)

Net Profit
Highest at CNY 16.31 MM
in the last five periods
MOJO Watch
Near term Net Profit trend is positive

Net Profit (CNY MM)

Net Profit
At CNY 16.31 MM has Grown at 93.56%
Year on Year (YoY)
MOJO Watch
Near term Net Profit trend is positive

Net Profit (CNY MM)

EPS
Highest at CNY 0.16
in the last five periods
MOJO Watch
Increasing profitability; company has created higher earnings for shareholders

EPS (CNY)

Raw Material Cost
Fallen by -4.53% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Enwei Pharmaceutical Co., Ltd.
Interest
At CNY 1.78 MM has Grown at 1,132.22%
over previous Semi-Annual period
MOJO Watch
Rising interest cost signifies increased borrowings

Interest Paid (CNY MM)

Operating Profit
Lowest at CNY 16.11 MM
in the last five periods
MOJO Watch
Near term Operating Profit trend is negative

Operating Profit (CNY MM)

Operating Profit Margin
Lowest at 8.28 %
in the last five periods
MOJO Watch
Company's profit margin has deteriorated

Operating Profit to Sales

Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."